Dr Ed Holland with Scotia Vision Consultants discuss “Semifluorinated alkane technology brings advantages for topical therapy” November 2016

Scotia Vision Co Edit a major new publication in Ocular Drug Delivery – November 2016

Choosing The Right Distributor! Original article from Scotia Vision with our European partner medeuronet

Enhancing The Delivery Of Topical Ocular Drops – by Scotia Vision – March 2016

ONdrug Delivery Publication – Expert Overview by Scotia Vision – Development of Sustained Release Ocular Delivery Technologies – January 2016

Ocular Drug Delivery: Challenges of Matching New Technologies with Drug Pharmacokinetics Scotia Vision co author – December 2015

Scotia Vision partners with medeuronet – October 2015

Scotia Vision (Tampa, FL) and medeuronet (Strasbourg, France and London) are pleased to announce the formation of a partnership designed to leverage each companies unique expertise — with medeuronet focusing on commercialization of new medical device technology in Europe.

Medeuronet is a pan-European company with a mission to accelerate time to market, ensure successful launches and drive profitable sales growth for innovative, start-up and established medical device companies. A strategic commercial partner, medeuronet works with medical device companies from pre-market launch preparation through to execution of sales strategy.

Founded in 2009, Scotia Vision focuses on ophthalmology and specializes in drug, drug delivery and medical devices for established and start-up companies in the US. Scotia Vision provides strategy, marketing, business development and sales planning expertise, as well as product launch preparation.

Ocular Drug Delivery – In Search of The Holy Grail – (Contribution by Scotia Vision) – September 2015

Scotia Vision Co-Chairs Ocular Drug Delivery Workshop – CRS Meeting Edinburgh Scotland- 25th July 2015, ‘Challenges of Matching New Technologies with Drug Pharmacokinetics’

Meeting the Challenges of Drug Delivery

Scotia Vision publication – Eye On Innovation (PDF, 14MB)

Scotia Vision client, Novaliq GmbH, Raises €13.9 million ($18.1 million) in 5th Round of Financing

Scotia Vision client, GrayBug, won the Invest Maryland Competition in the Healthcare category

Scotia Vision client Second Sight receives FDA approval for worlds first Bionic Eye

Is Increasing Drug Solubility The Answer To Improving Topical Eye Drug Delivery?

Click here to read the complete item. (PDF, 136 KB)

Scotia Vision Founder Michael O’Rourke presents at the 2011 annual “Controlled Release Society” meeting on “Market Development Strategies For Ocular Drug Delivery Systems”